Kala Pharmaceuticals Inc (KALA NASDAQ) stock market data APIs
$0.9254
-0.07(-7.6%)
as of October 21, 2025
Try our APIs with
free plan!
Kala Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Prev. Close
0.9254
Open
0.8515
High
0.9842
Low
0.8515
52 wk Range
0.8-20.6
Market Cap
9 198 K
Shares Outstanding
7 021 K
EPS
-1.71
Beta
-2.108
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kala Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kala Pharmaceuticals Inc data using free add-ons & libraries
Get Kala Pharmaceuticals Inc Fundamental Data
Kala Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -40 283 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-08
- EPS/Forecast: -2.93
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kala Pharmaceuticals Inc News
New
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
Shares of KALA BIO KALA have nosedived 88.3% in a month after the company announced the failure of a mid-stage study evaluating its only clinical pipeline candidate, KPI-012, for the treatment of pers...
Top Midday Decliners
MoonLake Immunotherapeutics (MLTX) shares sank 90% following the release of data from its late-stage PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
KALA BIO plunges 92% after phase 2 failure of eye condition drug
[Closeup irritated infected red bloodshot eyes, conjunctivitis] Andrei310/iStock via Getty Images * Shares of KALA Bio (NASDAQ:KALA [https://seekingalpha.com/symbol/KALA]) have plummeted ~92% in pr...
Is KALA BIO On The Verge Of A Pivotal Moment With KPI-012?
(RTTNews) - KALA BIO Inc. (KALA) is in focus, as anticipation builds around its upcoming clinical trial data for KPI-012, a novel stem cell-derived therapy targeting persistent corneal epithelial defe...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
